- Trials with a EudraCT protocol (2)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2 result(s) found for: Depth perception.
Displaying page 1 of 1.
EudraCT Number: 2018-003415-22 | Sponsor Protocol Number: AP-W-CLI-2018-8 | Start Date*: 2019-03-22 | |||||||||||
Sponsor Name:Aurealis Oy | |||||||||||||
Full Title: A Phase 1/2A clinical study to evaluate the safety, tolerability and efficacy of single and repeated doses of AUP1602-C as topical treatment of diabetic foot ulcers | |||||||||||||
Medical condition: Diabetic foot ulcers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021218-50 | Sponsor Protocol Number: AB09004 | Start Date*: 2011-05-25 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease | |||||||||||||
Medical condition: mild to moderate Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prohibited by CA) ES (Completed) SK (Prohibited by CA) PL (Completed) GR (Completed) GB (GB - no longer in EU/EEA) BG (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
